Individual generic drug information

cinnarizine

Reference monograph

Part of registered formulation

CINNARIZINE

Reference record: Cinnarizine
Source: BNF 80 (2020–2021)
Printed source pages: 479, 480
Age groups indexed: 2

Individual active ingredientSource records are displayed separately

Some source sections could not be separated reliably in the extraction. Review the printed source pages when a field is missing or incomplete.

Overview

Extracted information for Cinnarizine only.

Indications And Dose

Relief of symptoms of vestibular disorders, such as vertigo, tinnitus, nausea, and vomiting in Ménière’s disease ▶BY MOUTH ▶Child 5–11 years: 15 mg 3 times a day ▶Child 12–17 years: 30 mg 3 times a day ▶Adult: 30 mg 3 times a day Motion sickness ▶BY MOUTH ▶Child 5–11 years: Initially 15 mg, dose to be taken 2 hours before travel, then 7.5 mg every 8 hours if required, dose to be taken during journey ▶Child 12–17 years: Initially 30 mg, dose to be taken 2 hours before travel, then 15 mg every 8 hours if required, dose to be taken during journey ▶Adult: Initially 30 mg, dose to be taken 2 hours before travel, then 15 mg every 8 hours if required, dose to be taken during journey

Source page 479

Contra Indications

Avoid in Acute porphyrias p. 1120

Source page 479

Cautions

Epilepsy. glaucoma (in children). Parkinson’s disease (in adults). prostatic hypertrophy (in adults). pyloroduodenal obstruction. susceptibility to angle- closure glaucoma (in adults). urinary retention

Source page 479

Safety

Extracted information for Cinnarizine only.

Interactions

→Appendix 1: antihistamines, sedating

Source page 479

Side Effects

▶Common or very common Drowsiness. gastrointestinal discomfort. nausea. weight increased ▶Uncommon Fatigue. hyperhidrosis. vomiting ▶Frequency not known Dry mouth. gastrointestinal disorder . headache. jaundice cholestatic. movement disorders. muscle rigidity. parkinsonism. skin reactions. subacute cutaneous lupus erythematosus. tremor

Source page 479

Pregnancy

Manufacturer advises avoid; however, there is no evidence of teratogenicity. The use of sedating antihistamines in the latter part of the third trimester may cause adverse effects in neonates such as irritability, paradoxical excitability, and tremor.

Source page 479

Breast Feeding

Most antihistamines are present in breast milk in varying amounts; although not known to be harmful, most manufacturers advise avoiding their use in mothers who are breast-feeding.

Source page 479

Hepatic Impairment

Manufacturer advises caution in hepatic insufﬁciency—no information available.

Source page 479

Renal Impairment

Use with caution—no information available.

Source page 479

Dose and formulations

Extracted information for Cinnarizine only.

Medicinal Forms

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension Tablet CAUTIONARY AND ADVISORY LABELS 2 ▶Cinnarizine (Non-proprietary) Cinnarizine 15 mg Cinnarizine 15mg tablets | 84 tablet P £6.88 Nervous system DT = £4.75

Source page 480

Clinical care

Extracted information for Cinnarizine only.

Patient And Carer Advice

Driving and skilled tasks Drowsiness may affect performance of skilled tasks (e.g. cycling, driving); sedating effects enhanced by alcohol.

Source page 479

Dose text by age group

Filter the extracted dose blocks for this individual drug.

Children

First line only; read the complete Indications and dose section above.

15 mg 3 times a day

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 479

Children

First line only; read the complete Indications and dose section above.

30 mg 3 times a day

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 479

Adults

First line only; read the complete Indications and dose section above.

30 mg 3 times a day

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 479

Children

First line only; read the complete Indications and dose section above.

Initially 15 mg, dose to be taken

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 479

Children

First line only; read the complete Indications and dose section above.

Initially 30 mg, dose to be taken

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 479

Adults

First line only; read the complete Indications and dose section above.

Initially 30 mg, dose to be taken 2 hours before

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 479

Age labels are extracted from the printed dose headings and require clinical review. Confirm current local guidance, dose, route, formulation, contraindications and interactions before prescribing.

Individual generic drug information

cinnarizine

Reference monograph

Part of registered formulation

CINNARIZINE

Reference record: Cinnarizine
Source: BNF 80 (2020–2021)
Printed source pages: 479, 480
Age groups indexed: 2

Individual active ingredientSource records are displayed separately

Some source sections could not be separated reliably in the extraction. Review the printed source pages when a field is missing or incomplete.

Overview

Extracted information for Cinnarizine only.

Indications And Dose

Source page 479

Contra Indications

Avoid in Acute porphyrias p. 1120

Source page 479

Cautions

Source page 479

Safety

Extracted information for Cinnarizine only.

Interactions

→Appendix 1: antihistamines, sedating

Source page 479

Side Effects

Source page 479

Pregnancy

Source page 479

Breast Feeding

Most antihistamines are present in breast milk in varying amounts; although not known to be harmful, most manufacturers advise avoiding their use in mothers who are breast-feeding.

Source page 479

Hepatic Impairment

Manufacturer advises caution in hepatic insufﬁciency—no information available.

Source page 479

Renal Impairment

Use with caution—no information available.

Source page 479

Dose and formulations

Extracted information for Cinnarizine only.

Medicinal Forms

Source page 480

Clinical care

Extracted information for Cinnarizine only.

Patient And Carer Advice

Driving and skilled tasks Drowsiness may affect performance of skilled tasks (e.g. cycling, driving); sedating effects enhanced by alcohol.

Source page 479

Dose text by age group

Filter the extracted dose blocks for this individual drug.

Children

First line only; read the complete Indications and dose section above.

15 mg 3 times a day

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 479

Children

First line only; read the complete Indications and dose section above.

30 mg 3 times a day

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 479

Adults

First line only; read the complete Indications and dose section above.

30 mg 3 times a day

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 479

Children

First line only; read the complete Indications and dose section above.

Initially 15 mg, dose to be taken

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 479

Children

First line only; read the complete Indications and dose section above.

Initially 30 mg, dose to be taken

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 479

Adults

First line only; read the complete Indications and dose section above.

Initially 30 mg, dose to be taken 2 hours before

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 479

Age labels are extracted from the printed dose headings and require clinical review. Confirm current local guidance, dose, route, formulation, contraindications and interactions before prescribing.